|
| [January 11, 2013] |
 |
Research and Markets: Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis 2012
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/vxnpvt/fluad_seasonal)
has announced the addition of GlobalData's new report "Fluad (Seasonal
Influenza Vaccines) Forecast and Market Analysis" to their offering.
Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis.
Seasonal Influenza is a respiratory infection caused by influenza virus
that results in mild to severe symptoms, such as fever, cold and cough.
The market is heavily driven by the sales of prophylactic vaccine
treatments to prevent infection. Currently, trivalent intramuscular
vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's
Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of
the market. However, with the entrance of vaccies with novel routes of
administration, such as AstraZeneca's intranasal FluMist and Sanofi's
Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the
adoption of such vaccines over the traditional intramuscular vaccines.
GlobalData also anticipates that manufacturers that launch quadrivalent
formulations will steal market share, patient share, and revenue from
the trivalent influenza vaccines currently available.
Fluad is a trivalent, inactivated influenza vaccine that contains MF59
adjuvant, an oil-in-water emulsion containing squalene, polysorbate 80,
and sorbitan trioleate. The virus strains present in the vaccine are
grown in chicken eggs, harvested via centrifugation, inactivated with
formaldehyde, and the surface antigens are purified via further
centrifugation. The vaccine is indicated for immunization against
seasonal influenza via intramuscular injection, and the MF59 adjuvant
boosts the immune response of the recipient. Fluad was designed to
improve the efficacy of influenza vaccines in elderly patients, who have
waning immune systems. Fluad is marketed by Novartis in numerous
European and Asian counties, including France, German, Spain, and China.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Appendix
For more information visit http://www.researchandmarkets.com/research/vxnpvt/fluad_seasonal
Source (News - Alert): GlobalData

[ InfoTech Spotlight's Homepage ]
|